Skip to product information
1 of 1

GeneBio Systems

Recombinant Human PTK6/Brk Protein (GST Tag)

Recombinant Human PTK6/Brk Protein (GST Tag)

SKU:PKSH030398

Regular price $1,044.00 CAD
Regular price Sale price $1,044.00 CAD
Sale Sold out
Shipping calculated at checkout.

Size: 50μg

Storage: Store at < -20°C, stable for 6 months. Please minimize freeze-thaw cycles.

Shipping: This product is provided as liquid. It is shipped at frozen temperature with blue ice/gel packs. Upon receipt, store it immediately at < - 20°C.

Exp date: 12 months

Category ID_II: Recombinant Proteins

Category ID_III: Others

Abbreviation:

Target Synonym: BRK

Research Areas: Signal Transduction;Cancer;

Conjugation:

Target Species: Human

Expression Host: Baculovirus-Insect Cells

Application:

Fusion tag: N-GST

UNIProt ID: Q13882

Accession: NP_005966.1

Background: Tyrosine kinase (PTKs) is a protein that carry out tyrosine phosphorylation, which play a fundamental role in cell proliferation, survival, adhesion, and motility and have also been demenstrated to mediate malignant cell transformation. Overexpression of this protein in mammary epithelial cells leads to sensitization of the cells to epidermal growth factor and results in a partially transformed phenotype. Two classes of PTKs are present in cells: the transmembrane receptor PTKs and the non-receptor PTKs. Tyrosine kinase(PTKs)-6/ BRK is a cytoplasmic non-receptor protein kinase which may function as an intracellular signal transducer in epithelial tissues. Tyrosine kinase(PTKs)-6/ BRK has been shown to undergo autophosphorylation. It has been found that the constitutive expression of the tyrosine kinase(PTKs)-6/ BRK is in a large proportion of cutaneous T-cell lymphomas and other transformed T- and B-cell populations. State BRK expression was also induced in normal T-cells. In clinical, the cytoplasmic tyrosine kinase PTK6 (BRK) shows elevated expression in approximately two-thirds of primary breast tumours, and is implicated in EGF receptor-dependent signalling and epithelial tumorigenesis.

Concentration:

Activity: Not validated for activity

Sequence: Met 1-Thr 451

Purity: > 89 % as determined by reducing SDS-PAGE.

Formulation: Supplied as sterile solution of 50mM Tris, 100mM NaCl, pH 8.0, 10% glycerol

Reconstitution: Not Applicable

Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.

Calculated MW: 78.0 kDa

ObservedMW: 70 kDa

View full details